IHT Wealth Management’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

IHT Wealth Management’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,433	Closed	-$237K	–	951
2022 Q3	$237K	Buy	11,433 +240	+2%	+$5.84K	0.02%	710
2022 Q2	$260K	Sell	11,193 -525	-4%	-$12.5K	0.02%	575
2022 Q1	$321K	Sell	11,718 -245	-2%	-$6.9K	0.02%	546
2021 Q4	$426K	Buy	11,963 +1,370	+13%	+$51.4K	0.03%	484
2021 Q3	$434K	Sell	10,593 -1,270	-11%	-$53.6K	0.04%	474
2021 Q2	$475K	Buy	+11,863	New	+$443K	0.03%	549

Other funds holding GERM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IHT Wealth Management's GERM Position: Q4 2022 in Review

IHT Wealth Management sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q4 2022, closing a stake of 11,433 shares — an estimated $237K sold.

IHT Wealth Management first reported a position in GERM in Q2 2021 and held it in 6 quarters. The position peaked at $475K in Q2 2021. 24 funds tracked by Wall St. Rank hold GERM as of Q4 2022.

IHT Wealth Management reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q4 2022 after selling out during the quarter.
IHT Wealth Management sold 11,433 Amplify Treatments, Testing and Advancements ETF shares in Q4 2022, an estimated $237K.
IHT Wealth Management first reported a position in Amplify Treatments, Testing and Advancements ETF in Q2 2021 and held it in 6 quarters.
IHT Wealth Management's Amplify Treatments, Testing and Advancements ETF position peaked at $475K in Q2 2021.
24 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q4 2022.

Based on IHT Wealth Management's 13F filing for Q4 2022, filed 15 Feb 2023.